Sunesis Pharmaceuticals Inc. Files SEC Form 8-K Filing on June 10, 2015

Strategic Insights -

According to a U.S. Securities and Exchange Commission (SEC) filing, Sunesis Pharmaceuticals Inc. reported significant corporate changes on June 10, 2015. The company is a pharmaceutical manufacturer with its main operations in South San Francisco, California. As a publicly-traded company, Sunesis Pharmaceuticals is required to submit regular financial statements and reports to the SEC, ensuring transparency and accountability to its investors.

Key Takeaways:

  • Sunesis Pharmaceuticals Inc. filed a Form 8-K with the SEC on June 10, 2015, reporting material events and corporate changes.
  • The company is a U.S.-based pharmaceutical manufacturer, operating under the SIC code 2834 for Pharmaceutical Preparations.
  • The Form 8-K filing is a mandatory report required for publicly-traded companies to disclose significant events that have not been previously reported in their quarterly or annual financial statements.
  • Sunesis Pharmaceuticals' SEC filing contact information is 395 Oyster Point Boulevard, Suite 400, South San Francisco, CA 94080, with a phone number of 650-266-3500.
  • The filing is available on the SEC website, accessible through www.sec.gov/Archives/edgar/data/1061027/0001193125-15-219293-index.html.

Statistics:

  • Date of SEC filing: June 10, 2015
  • SIC code for Sunesis Pharmaceuticals Inc.: 2834, Pharmaceutical Preparations
  • SEC file number: 0001193125-15-219293
  • Number of documents filed with Form 8-K: 1
  • Contact information for Sunesis Pharmaceuticals: 395 Oyster Point Boulevard, Suite 400, South San Francisco, CA 94080, 650-266-3500

Sources:

  • U.S. Securities and Exchange Commission
  • NewsRx editors' additional information about Form 8-K
  • SEC filing for Sunesis Pharmaceuticals Inc. (Form 8-K, June 10, 2015)
  • SEC website (www.sec.gov/Archives/edgar/data/1061027/0001193125-15-219293-index.html)